Vincristine

Generic Name
Vincristine
Brand Names
Marqibo, Vincasar
Drug Type
Small Molecule
Chemical Formula
C46H56N4O10
CAS Number
57-22-7
Unique Ingredient Identifier
5J49Q6B70F
Background

Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristin...

Indication

Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).

Associated Conditions
Acute Lymphoblastic Leukemia (ALL), Choriocarcinoma, Chronic Lymphocytic Leukemia, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Hepatoblastomas, Hodgkin's Lymphoma, Immune Thrombocytopenia (ITP), Kaposi's Sarcoma, Multiple Myeloma (MM), Neuroblastoma (NB), Non-Hodgkin's Lymphoma (NHL), Ovarian germ cell tumour, Pheochromocytoma, Relapsed Acute Lymphoblastic Leukemia (ALL), Retinoblastoma, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Wilms' tumor, Advanced Thymoma
Associated Therapies
-
Clinical Trials
Related News

Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Elderly/Unfit Ph- B-ALL

First Posted Date
2024-04-26
Last Posted Date
2024-04-26
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Target Recruit Count
53
Registration Number
NCT06387121

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma

First Posted Date
2024-04-10
Last Posted Date
2024-12-18
Lead Sponsor
Celgene
Target Recruit Count
850
Registration Number
NCT06356129
Locations
🇺🇸

Cancer Care Specialists, Reno, Nevada, United States

🇺🇸

Local Institution - 0498, East Brunswick, New Jersey, United States

🇺🇸

Moffitt Cancer Center, Tampa, Florida, United States

and more 344 locations

Ma-Spore ALL 2020 Study

First Posted Date
2024-03-28
Last Posted Date
2024-03-28
Lead Sponsor
National University Hospital, Singapore
Target Recruit Count
500
Registration Number
NCT06336395
Locations
🇲🇾

University Malaya Medical Centre, Kuala Lumpur, Malaysia

🇲🇾

Subang Jaya Medical Centre, Kuala Lumpur, Malaysia

🇸🇬

KK Women's and Children's Hospital, Singapore, Singapore

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

First Posted Date
2024-03-19
Last Posted Date
2024-12-04
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
171
Registration Number
NCT06317662

A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma

First Posted Date
2024-03-15
Last Posted Date
2024-03-15
Lead Sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Target Recruit Count
300
Registration Number
NCT06313996

Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

First Posted Date
2024-03-04
Last Posted Date
2024-12-16
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
850
Registration Number
NCT06289673
Locations
🇺🇸

United States, Tennessee St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5

First Posted Date
2024-02-28
Last Posted Date
2024-10-11
Lead Sponsor
The Lymphoma Academic Research Organisation
Target Recruit Count
790
Registration Number
NCT06284122
Locations
🇫🇷

HOPITAL HENRI MONDOR - Unité Hémopathies Lymphoïdes, Créteil, France

🇫🇷

GUSTAVE ROUSSY CANCER CAMPUS GRAND PARIS - Département Médecine Oncologique, Villejuif, France

🇫🇷

CH ANNECY GENEVOIS - SITE D'ANNECY - Service Hématologie, Pringy, France

and more 46 locations

Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma

First Posted Date
2024-02-09
Last Posted Date
2024-04-16
Lead Sponsor
Guangzhou Lupeng Pharmaceutical Company LTD.
Target Recruit Count
112
Registration Number
NCT06251180
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma

First Posted Date
2024-02-08
Last Posted Date
2024-07-23
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
40
Registration Number
NCT06249191
Locations
🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma

First Posted Date
2024-01-23
Last Posted Date
2024-08-19
Lead Sponsor
Stichting Hemato-Oncologie voor Volwassenen Nederland
Target Recruit Count
324
Registration Number
NCT06220032
Locations
🇳🇱

NL-Breda-AMPHIA, Breda, Netherlands

🇳🇱

NL-Almelo-ZGTALMELO, Almelo, Netherlands

🇳🇱

NL-Amstelveen-AMSTELLAND, Amstelveen, Netherlands

and more 22 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy